Anti‐Hu‐Associated Autoimmune Limbic Encephalitis in a Patient with PD‐1 Inhibitor‐Responsive Myxoid Chondrosarcoma

por Papadopoulos, Kyriakos P., Romero, Rebecca S., Gonzalez, Gabriela, Dix, James E., Lowy, Israel, Fury, Matthew
Publicado no Oncologist (2017)

Safety and tolerability of quizartinib, a FLT3 inhibitor, in advanced solid tumors: a phase 1 dose-escalation trial

por Papadopoulos, Kyriakos P., Ben-Ami, Eytan, Patnaik, Amita, Trone, Denise, Li, Jianke, Demetri, George D.
Publicado no BMC Cancer (2018)

Evaluation of the pharmacokinetic drug interaction potential of tivantinib (ARQ 197) using cocktail probes in patients with advanced solid tumours

por Tachibana, Masaya, Papadopoulos, Kyriakos P., Strickler, John H., Puzanov, Igor, Gajee, Roohi, Wang, Yibin, Zahir, Hamim
Publicado no Br J Clin Pharmacol (2017)

Phase I, first-in-human trial of programmed cell death receptor-1 (PD-1) inhibitor, JTX-4014, in adult patients with advanced, refractory, solid tumors

por Papadopoulos, Kyriakos P., Lakhani, Nehal, Falchook, Gerald S., Riley, Gosia, Baeck, Johan, Brown, Karen S., Gordon, Gilad, Le, Lidya, Wang, Judy S.
Publicado no Cancer Immunol Immunother (2020)

A phase 1 dose escalation and expansion study of Tarextumab (OMP-59R5) in patients with solid tumors

por Smith, David C., Chugh, Rashmi, Patnaik, Amita, Papadopoulos, Kyriakos P., Wang, Min, Kapoun, Ann M., Xu, Lu, Dupont, Jakob, Stagg, Robert J., Tolcher, Anthony
Publicado no Invest New Drugs (2018)

Physiologically‐based pharmacokinetic modelling to predict oprozomib CYP3A drug–drug interaction potential in patients with advanced malignancies

por Ou, Ying, Xu, Yang, Gore, Lia, Harvey, R. Donald, Mita, Alain, Papadopoulos, Kyriakos P., Wang, Zhengping, Cutler, Richard E., Pinchasik, Dawn E., Tsimberidou, Apostolia M.
Publicado no Br J Clin Pharmacol (2018)

A Phase I study to evaluate the safety and antitumor activity of durvalumab (MEDI4736) in combination with tremelimumab in patients with advanced solid tumors

por Papadopoulos, Kyriakos P, Tsai, Frank, Hamid, Omid, Xiao, Feng, Steele, Keith E, Rebelatto, Marlon C, Robbins, Paul B, Karakunnel, Joyson J, Lai, Dominic W, Mahipal, Amit
Publicado no J Immunother Cancer (2015)

Preclinical investigations and a first-in-human phase I trial of M4112, the first dual inhibitor of indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase 2, in patients with...

por Naing, Aung, Eder, Joseph P, Piha-Paul, Sarina A, Gimmi, Claude, Hussey, Elizabeth, Zhang, Sen, Hildebrand, Vera, Hosagrahara, Vinayak, Habermehl, Christina, Moisan, Jacques, Papadopoulos, Kyriakos P
Publicado no J Immunother Cancer (2020)

Fixed Dose of Cemiplimab in Patients with Advanced Malignancies Based on Population Pharmacokinetic Analysis

por Paccaly, Anne J., Migden, Michael R., Papadopoulos, Kyriakos P., Yang, Feng, Davis, John D., Rippley, Ronda K., Lowy, Israel, Fury, Matthew G., Stankevich, Elizabeth, Rischin, Danny
Publicado no Adv Ther (2021)

Pegilodecakin as monotherapy or in combination with anti‐PD‐1 or tyrosine kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma: Final results of cohor...

por Tannir, Nizar M., Papadopoulos, Kyriakos P., Wong, Deborah J., Aljumaily, Raid, Hung, Annie, Afable, Manuel, Kim, Jong Seok, Ferry, David, Drakaki, Alexandra, Bendell, Johanna, Naing, Aung
Publicado no Int J Cancer (2021)

Phase I Dose-Escalation Study of EZN-2208 (PEG-SN38), a Novel Conjugate of Poly(ethylene) Glycol and SN38, Administered Weekly in Patients With Advanced Cancer

por Patnaik, Amita, Papadopoulos, Kyriakos P., Tolcher, Anthony W., Beeram, Muralidhar, Urien, Saïk, Schaaf, Larry J., Tahiri, Sanaa, Bekaii-Saab, Tanios, Lokiec, François M., Rezaï, Keyvan, Buchbinder, Aby
Publicado em 2013

A phase I/II study of carfilzomib 2–10-min infusion in patients with advanced solid tumors

por Papadopoulos, Kyriakos P., Burris, Howard A., Gordon, Michael, Lee, Peter, Sausville, Edward A., Rosen, Peter J., Patnaik, Amita, Cutler, Richard E., Wang, Zhengping, Lee, Susan, Jones, Suzanne F., Infante, Jeffery R.
Publicado em 2013

Correction to: A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer

por Patnaik, Amita, Gordon, Michael, Tsai, Frank, Papadopoulos, Kyriakos P., Rasco, Drew, Beeram, Muralidhar, Fu, Siqing, Janku, Filip, Hynes, Scott M., Gundala, Sushma R., Willard, Melinda D., Zhang, Wei, Lin, Aimee Bence, Hong, David
Publicado no Cancer Chemother Pharmacol (2018)

Multiepitope CD8(+) T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting

por Dutoit, Valérie, Taub, Robert N., Papadopoulos, Kyriakos P., Talbot, Susan, Keohan, Mary-Louise, Brehm, Michelle, Gnjatic, Sacha, Harris, Paul E., Bisikirska, Brygida, Guillaume, Philippe, Cerottini, Jean-Charles, Hesdorffer, Charles S., Old, Lloyd J., Valmori, Danila
Publicado em 2002

A phase 1 study of the BCL2-targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumors

por Tolcher, Anthony W., Rodrigueza, Wendi V., Rasco, Drew W., Patnaik, Amita, Papadopoulos, Kyriakos P., Amaya, Alex, Moore, Timothy D., Gaylor, Shari K., Bisgaier, Charles L., Sooch, Mina P., Woolliscroft, Michael J., Messmann, Richard A.
Publicado em 2013

A single supratherapeutic dose of ridaforolimus does not prolong the QTc interval in patients with advanced cancer

por Lush, Richard M., Patnaik, Amita, Sullivan, Daniel, Papadopoulos, Kyriakos P., Trucksis, Michele, McCrea, Jacqueline, Cerchio, Kristine, Li, Xiaodong, Stroh, Mark, Selverian, Diana, Orford, Keith, Ebbinghaus, Scot, Agrawal, Nancy, Iwamoto, Marian, Wagner, John A., Tolcher, Anthony
Publicado em 2012

A First‐in‐Human Phase I Study of OPB‐111077, a Small‐Molecule STAT3 and Oxidative Phosphorylation Inhibitor, in Patients with Advanced Cancers

por Tolcher, Anthony, Flaherty, Keith, Shapiro, Geoffrey I., Berlin, Jordan, Witzig, Thomas, Habermann, Thomas, Bullock, Andrea, Rock, Edwin, Elekes, Agnes, Lin, Chester, Kostic, Dusan, Ohi, Naoto, Rasco, Drew, Papadopoulos, Kyriakos P., Patnaik, Amita, Smith, Lon, Cote, Gregory M.
Publicado no Oncologist (2018)

CD8+ T cell stimulation with pegylated recombinant human IL-10 in the patient with advanced solid tumors - a Phase I study

por Naing, Aung, Infante, Jeffrey R, Papadopoulos, Kyriakos P, Autio, Karen A, Wong, Deborah J, Falchook, Gerald S, Patel, Manish R, Pant, Shubham, Whiteside, Melinda, Bendell, Johanna, Bauer, Todd M, Janku, Filip, Javle, Milind, Colen, Rivka, Tannir, Nizar, Oft, Martin
Publicado no J Immunother Cancer (2015)

Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors

por Molife, L Rhoda, Yan, Li, Vitfell-Rasmussen, Joanna, Zernhelt, Adriane M, Sullivan, Daniel M, Cassier, Philippe A, Chen, Eric, Biondo, Andrea, Tetteh, Ernestina, Siu, Lillian L, Patnaik, Amita, Papadopoulos, Kyriakos P, de Bono, Johann S, Tolcher, Anthony W, Minton, Susan
Publicado em 2014

Clinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits: application of a novel pharmacodynamic assay

por Lee, Susan J., Levitsky, Konstantin, Parlati, Francesco, Bennett, Mark K., Arastu‐Kapur, Shirin, Kellerman, Lois, Woo, Tina F., Wong, Alvin F., Papadopoulos, Kyriakos P., Niesvizky, Ruben, Badros, Ashraf Z., Vij, Ravi, Jagannath, Sundar, Siegel, David, Wang, Michael, Ahmann, Gregory J., Kirk, Christopher J.
Publicado no Br J Haematol (2016)